Rajeev Saggar Sells 6,249 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the sale, the insider now directly owns 270,388 shares of the company’s stock, valued at $3,185,170.64. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Friday, October 18th, Rajeev Saggar sold 2,526 shares of Liquidia stock. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94.

Liquidia Stock Performance

LQDA opened at $12.14 on Thursday. The stock’s 50 day moving average price is $11.23 and its 200-day moving average price is $11.02. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.99. The stock has a market capitalization of $1.03 billion, a PE ratio of -7.45 and a beta of 0.23.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LQDA. Bank of New York Mellon Corp lifted its position in shares of Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after purchasing an additional 32,076 shares during the period. Rhumbline Advisers raised its stake in Liquidia by 12.4% in the second quarter. Rhumbline Advisers now owns 80,164 shares of the company’s stock worth $962,000 after buying an additional 8,871 shares in the last quarter. Arizona State Retirement System lifted its holdings in Liquidia by 10.7% in the second quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after buying an additional 1,341 shares during the period. Quest Partners LLC bought a new stake in Liquidia during the 2nd quarter valued at approximately $27,000. Finally, Profund Advisors LLC grew its holdings in shares of Liquidia by 31.6% during the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after acquiring an additional 3,466 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LQDA has been the topic of a number of recent research reports. Scotiabank started coverage on Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Wells Fargo & Company assumed coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Lifesci Capital assumed coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).